KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) EBT (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed EBT for 11 consecutive years, with -$162.5 million as the latest value for Q4 2025.

  • Quarterly EBT fell 108.79% to -$162.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$610.5 million through Dec 2025, down 51.15% year-over-year, with the annual reading at -$610.5 million for FY2025, 51.15% down from the prior year.
  • EBT hit -$162.5 million in Q4 2025 for CRISPR Therapeutics AG, down from -$105.8 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $763.4 million in Q2 2021 to a low of -$518.5 million in Q4 2021.
  • Historically, EBT has averaged -$90.6 million across 5 years, with a median of -$118.6 million in 2022.
  • Biggest YoY gain for EBT was 1062.91% in 2021; the steepest drop was 308.64% in 2021.
  • Year by year, EBT stood at -$518.5 million in 2021, then surged by 76.59% to -$121.4 million in 2022, then soared by 173.81% to $89.6 million in 2023, then crashed by 186.9% to -$77.8 million in 2024, then crashed by 108.79% to -$162.5 million in 2025.
  • Business Quant data shows EBT for CRSP at -$162.5 million in Q4 2025, -$105.8 million in Q3 2025, and -$207.3 million in Q2 2025.